Structure-activity relationship analyses of glycyrrhetinic acid derivatives as anticancer agents

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 10, 2011, Pages 881-887

  Lallemand, B ^a   Gelbcke, M ^a   Dubois, J ^a   Prevost M ^a   Jabin, I ^a   Kiss, R ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Cancer; Glycyrrhetinic acid derivatives; Ppar; Proteasome inhibitors; Structure activity relationship

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; CARFILZOMIB; CEP 18770; GLYCYRRHETINIC ACID DERIVATIVE; MLN 9708; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PR 047; PR 407; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; GLYCYRRHIZA GLABRA; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; PROGNOSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GLYCYRRHETINIC ACID; HUMANS; PPAR GAMMA; PROTEASOME ENDOPEPTIDASE COMPLEX; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79960998961     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955711796575443     Document Type: Article

References (62)

1. Simpson, C.D.; Anyiwe, K.; Schimmer, A.D. Anoikis resistanceand tumor metastasis. Cancer Lett., 2008, 272, 177-185.
2. Lamoral-Theys, D.; Pottier, L.; Kerff, F.; Dufrasne, F.; Proutière, F.; Wauthoz, N.; Neven, P.; Ingrassia, L.; Van Antwerpen, P.; Lefranc, F.; Gelbcke, M.; Pirotte, B.; Kraus, J.L.; Nève, J.; Kornienko, A.; Kiss, R.; Dubois, J. Simple di- and trivanillates exhibitcytostatic properties toward cancer cells resistant to proapoptoticstimuli. BioOrg. Med. Chem., 2010, 18, 3823-3833.
3. Mathieu, A.; Remmelink, M.; D'Haene, N.; Penant, S.; Gaussin, J.F.; Van Ginckel, R.; Darro, F.; Kiss, R.; Salmon, I. Developmentof a chemoresistant orthotopic human nonsmall cell lung carcinomamodel in nude mice. Cancer, 2004, 101, 1908-1918.
4. Han, S.; Roman, J., Targeting apoptotic signalling pathways inhuman lung cancer. Curr. Cancer Drug Targets, 2010, 10, 566-574.
5. Soengas, M.S.; Lowe, S.W. Apoptosis and melanoma chemoresistance. Oncogene, 2003, 22, 3138-3151.
6. Mathieu, V.; Pirker, C.; Martin de Lassalle, E.; Vernier, M.; Mijatovic, T.; De Nève, N.; Gaussin, J.F.; Dehoux, M.; Lefranc, F.; Berger, W.; Kiss, R. The sodium pump alpha-1 subunit: a diseaseprogression-related target for metastatic melanoma treatment. J.Cell Mol. Med., 2009, 13, 3960-3972.
7. Wong, H.H.; Lemoine, N.R. Pancreatic cancer: molecular pathogenesisand new therapeutic targets. Nat. Rev. Gastroenterol. Hepatol.,2009, 6, 412-422.
8. D'Amico, T.A.; Harpole, D.H. Jr. Molecular biology of esophagealcancer. Chest Surg. Clin. N. Am., 2000, 10, 451-469.
9. Bruyère, C.; Lonez, C.; Duray, A.; Cludts, S.; Ruysschaert, J.M.; Saussez, S.; Yeaton, P.; Kiss, R.; Mijatovic, T. Considering temozolomideas a novel potential treatment for oesophageal cancer.Cancer, 2011, 117, 2004-2016.
10. Lefranc, F.; Brotchi, J.; Kiss, R. Possible future issues in the treatmentof glioblastomas, with a special emphasis on cell migrationand the resistance of migrating glioblastoma cells to apoptosis. J.Clin. Oncol., 2005, 23, 2411-2422.
11. Lefranc, F.; Facchini, V.; Kiss, R. Pro-autophagic drugs: A novelmeans to combat apoptosis-resistant cancers, with a special emph asison glioblastomas. Oncologist, 2007, 12, 1395-1403.
12. Lefranc, F.; Kiss, R. The sodium pump alpha-1 subunit as a potentialtarget to combat apoptosis-resistant glioblastomas. Neoplasia,2008, 10, 198-206.
13. Anuchapreeda, S.; Leechanachai, P.; Smith, M.M.; Ambudkar, S.V.; Limtrakul, P.N. type=contributor>Modulation of P-glycoprotein expression andfunction by curcumin in multidrug-resistant human KB cells. Biochem.Pharmacol., 2002, 64, 573-582.
14. Mayur, Y.C.; Peters, G.J.; Prasad, V.V.; Lemo, C.; Sathish, N.K. Design of new drug molecules to be used in reversing multidrug resistancein cancer cells. Curr. Cancer Drug Targets, 2009, 9, 298-306.
15. Gossage, L.; Eisen, T. Targeting multiple kinase pathways: achange in paradigm. Clin. Cancer Res., 2010, 16, 1973-1978.
16. Knight, Z.A.; Lin, H.; Shokat, K.M. Targeting the cancer kinomethrough polypharmacology. Nat. Rev. Cancer, 2010, 10, 130-137.
17. Fedorov, O.; Müller, S.; Knapp, S. The (un)target cancer kinome.Nat. Chem. Biol., 2010, 6, 166-169.
18. Obolentseva, G. V.; Litvinenko, V. I.; Ammosov, A. S.; Popova, T.P.; Sampiev, A. M. Pharmacological and therapeutic properties oflicorice preparations. Pharm. Chem. J., 1999, 33, 427-434.
19. Abe, H.; Ohya, N.; Yamamoto, K. F.; Shibuya, T.; Arichi, S.; Odashima, S. Effects of glycyrrhizin and glycyrrhetinic acid ongrowth and melanogenesis in cultured B16 melanoma cells. Eur. J.Cancer Clin. Oncol., 1987, 23, 1549-1555.
20. Okamoto, H.; Yoshida, D.; Mizusaki, S. Inhibition of 12-Otetradecanoylphorbol-13-acetate-induced induction in Epstein-Barrvirus early antigen in Raji cells. Cancer Lett., 1983, 19, 47-53.
21. Gao, Y.; Guo, X.; Li, X.; Liu, D.; Song, D.; Xu, Y.; Sun, M.; Jing, Y.; Zhao, L. The synthesis of glycyrrhetinic acid derivatives containingA nitrogen heterocycle and their antiproliferative effects inhuman leukemia cells. Molecules, 2010, 15, 4439-4449.
22. Hibasami, H.; Iwase, H.; Yoshioka, K.; Takahashi, H. Glycyrrheticacid (a metabolic substance and aglycon of glycyrrhizin) inducesapoptosis in human hepatoma, promyelotic leukemia and stomachcancer cells. Int. J. Mol. Med., 2006, 17, 215-219.
23. Isbrucker, R. A.; Burdock, G. A. Risk and safety assessment on theconsumption of licorice root (Glycyrrhiza sp.), its extract and powderas a food ingredient, with emphasis on the pharmacology andtoxicology of glycyrrhizin. Regul. Toxicol. Pharmacol., 2006, 46,167-192.
24. Zhang, M.-Z.; Xu, J.; Yao, B.; Yin, H.; Cai, Q.; Shrubsole, M. J.; Chen, X.; Kon, V.; Zheng, W.; Pozzi, A.; Harris, R. C. Inhibitionof 11beta -hydroxysteroid dehydrogenase type II selectively blocksthe tumor COX-2 pathway and suppresses colon carcinogenesis inmice and humans. J. Clin. Invest., 2009, 119, 876-885.
25. Satomi, Y.; Nishino, H.; Shibata, S. Glycyrrhetinic acid and relatedcompounds induce G1 arrest and apoptosis in human hepatocellularcarcinoma HepG2. Anticancer Res., 2005, 25, 4043-4047.
26. Hawthorne, S.; Gallagher, S. Effects of glycyrrhetinic acid andliquorice extract on cell proliferation and prostate-specific antigensecretion in LNCaP prostate cancer cells. J. Pharm. Pharmacol.,2008, 60, 661-666.
27. Chintharlapalli, S.; Papineni, S.; Jutooru, I.; McAlees, A.; Safe, S. Structure-dependent activity of glycyrrhetinic acid derivatives asperoxisome proliferator-activated receptor gamma agonists in coloncancer cells. Mol. Cancer Ther., 2007, 6, 1588-1598.
28. Chintharlapalli, S.; Papineni, S.; Konopleva, M.; Andreef, M.; Samudio, I.; Safe, S. 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acidand related compounds inhibit growth of colon cancer cells throughperoxisome proliferator-activated receptor gamma-dependent and -independent pathways. Mol. Pharmacol., 2005, 68, 119-128.
29. Liu, D.; Song, D.; Guo, G.; Wang, R.; Lv, J.; Jing, Y.; Zhao, L. Thesynthesis of 18beta -glycyrrhetinic acid derivatives which have increasedantiproliferative and apoptotic effects in leukemia cells.Bioorg. Med. Chem., 2007, 15, 5432-5439.
30. Subba Rao, G. S. R.; Kondaiah, P.; Singh, S. K.; Ravanan, P.; Sporn, M. B. Chemical modifications of natural triterpenesglycyrrhetinicand boswellic acids: evaluation of their biologicalactivity. Tetrahedron, 2008, 64, 11541-11548.
31. Tatsuzaki, J.; Taniguchi, M.; Bastow, K. F.; Nakagawa-Goto, K.; Morris-Natschke, S. L.; Itokawa, H.; Baba, K.; Lee, K.-H. Antitumoragents: Novel glycyrrhetinic acid-dehydrozingerone conjugatesas cytotoxic agents. Bioorg. Med. Chem., 2007, 15, 6193-6199.
32. Salvi, M.; Fiore, C.; Armanini, D.; Toninello, A. Glycyrrhetinicacid-induced permeability transition in rat liver mitochondria. Biochem.Pharmacol., 2003, 66, 2375-2379.
33. Lee, C. S.; Kim, Y. J.; Lee, M. S.; Han, E. S.; Lee, S. J. 18beta -Glycyrrhetinic acid induces apoptotic cell death in SiHa cells andexhibits a synergistic effect against antibiotic anti-cancer drug toxicity. Life Sci., 2008, 83, 481-489.
34. Yu, T.; Yamaguchi, H.; Noshita, T.; Kidachi, Y.; Umetsu, H.; Ryoyama, K. Selective cytotoxicity of glycyrrhetinic acid againsttumorigenic r/m HM-SFME-1 cells: Potential involvement of HRasdownregulation. Toxicol. Lett., 2010, 192, 425-430.
35. Yamaguchi, H.; Noshita, T.; Yu, T.; Kidachi, Y.; Kamiie, K.; Umetsu, H.; Ryoyama, K. Novel effects of glycyrrhetinic acid onthe central nervous system tumorigenic progenitor cells: Inductionof actin disruption and tumor cell-selective toxicity. Eur. J. Med.Chem., 2010, 45, 2943-2948.
36. Nabekura, T.; Yamaki, T.; Ueno, K.; Kitagawa, S. Inhibition of Pglycoproteinand multidrug resistance protein 1 by dietary phytochemicals.Cancer Chemother. Pharmacol., 2008, 62, 867-873.
37. Nakagawa-Goto, K.; Nakamura, S.; Bastow, K. F.; Nyarko, A.; Peng, C.-Y.; Lee, F.-Y.; Lee, F.-C.; Lee, K.-H. Antitumor agents.256. Conjugation of paclitaxel with other antitumor agents: evaluationof novel conjugates as cytotoxic agents. Bioorg. Med. Chem.Lett., 2007, 17, 2894-2898.
38. Jutooru, I.; Chadalapaka, G.; Chintharlapalli, S.; Papineni, S.; Safe, S. Induction of apoptosis and nonsteroidal anti-inflammatory drugactivatedgene 1 in pancreatic cancer cells by a glycyrrhetinic acidderivative. Mol. Carcinog., 2009, 48, 692-702.
39. Pang, X.; Zhang, L.; Wu, Y.; Lin, L.; Li, J.; Qu, W.; Safe, S.; Liu, M. Methyl 2-cyano-3,11-dioxo-18-olean-1,12-dien-30-oate, a derivativeof glycyrrhetinic acid, functions as a potent angiogenesisinhibitor. J. Pharmacol. Exp. Ther., 2010, 335, 172-179.
40. Terasawa, T.; Okada, T.; Nishino, H. Antitumor promoter activityof modified glycyrrhetinic acid derivatives. Synthesis and structure-activity relationships. Eur. J. Med. Chem., 1992, 27, 689-692.
41. Honda, T.; Rounds, B. V.; Bore, L.; Finlay, H. J.; Favaloro, F. G., Jr.; Suh, N.; Wang, Y.; Sporn, M. B.; Gribble, G. W. Syntheticoleanane and ursane triterpenoids with modified rings A and C: Aseries of highly active inhibitors of nitric oxide production inmouse macrophages. J. Med. Chem., 2000, 43, 4233-4246.
42. Chadalapaka, G.; Jutooru, I.; McAlees, A.; Stefanac, T.; Safe, S. Structure-dependent inhibition of bladder and pancreatic cancercell growth by 2-substituted glycyrrhetinic and ursolic acid derivatives.Bioorg. Med. Chem. Lett., 2008, 18, 2633-2639.
43. Logashenko, E. B.; Salomatina, O.V.; Markov, A.V.; Korchagina, D. V.; Salakhutdinov, N. F.; Tolstikov, G.A.; Vlassov, V. V.; Zenkova, M.A. Synthesis and pro-apoptotic activity of novel glycyrrhetinicacid derivatives. Chembiochem, 2001, 12, 784-794.
44. Shi, J.-h.; Xiao, J.-h.; Wei, D.-Z. Synthesis of biotinylated 18beta -glycyrrhetinic acid and its effect on tumor cells activity. Med.Chem. Res., 2009, 18, 538-544.
45. Chen, D.; Dou, Q.P. The ubiquitin-proteasome system as a prospectivemolecular target for cancer treatment and prevention.Curr. Protein Pept. Sci., 2010, 11, 459-470.
46. Tsukamoto, S.; Yokosawa, H. Targeting the proteasome pathway.Expert Opin. Ther. Targets, 2009, 13, 605-621.
47. Yang, H.; Liu, J.; Dou, Q.P. Targeting tumor proteasome withtraditional Chinese medicine. Curr. Drug Discov. Technol., 2010,7, 46-53.
48. Dick, L.R.; Fleming, P.E. Building on bortezomib: secondgenerationproteasome inhibitors as anti-cancer therapy. Drug Discov.Today, 2010, 15, 243-249.
49. Wu WK, Cho CH, Lee CW, Wu K, Fan D, Yu J, Sung, J.J. Proteasomeinhibition: a new therapeutic strategy to cancer treatment. Cancer Lett., 2010, 293, 15-22.
50. Huang, L.; Yu, D.; Ho, P.; Qian, K.; Lee, K.H.; Chen, C.H. Synthesisand proteasome inhibition of glycyrrhetinic acid derivatives.Bioorg. Med. Chem., 2008, 16, 6696-6701.
51. Stancovski, I.; Gonen, H.; Orian, A.; Schwartz, A.L.; Ciechanover, A. Degradation of the proto-oncogene product c-Fos by the ubiquitinproteolytic system in vivo and in vitro: Identification and characterizationof the conjugating enzymes. Mol. Cell. Biol., 1995, 15,7106-7116.
52. Zhu, J.; Gianni, M.; Kopf, E.; Honoré, N.; Chelbi-Alex, M.; Koken, M.; Quignon, F.; Rochette-Egly, C.; de Thé, H. Retinoic acid inducesproteasome-dependent degradation of retinoic acid receptoralpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc.Natl. Acad. Sci. USA, 1999, 96, 14807-14812.
53. Stewart, D.; Kazemi, S.; Li, S.; Massimi, P.; Banks, L.; Koromilas, A.E.; Matlasshewski, G. Ubiquitination and proteasome degradationof the E6 proteins of human papillomavirus types 11 and 18. J.Gen. Virol., 2004, 85, 1419-1426.
54. Psahoulia, F.H.; Moumtzi, S.; Roberts, M.L.; Sasazuki, T.; Shirasawa, S.; Pintzas, A. Quercetin mediates preferential degradationof oncogenic Ras and causes autophagy in Ha-Ras-transformedhuman colon cells. Carcinogenesis, 2007, 28, 1021-1031.
55. Penna, F.; Bonelli, G.; Baccino, F.M.; Costelli, P. Cytotoxic propertiesof clofibrate and other peroxisome proliferators: relevance tocancer progression. Curr. Med. Chem., 2010, 17, 309-320.
56. Pozzi, A.; Capdevilla, J.H. PPARalpha ligands as antitumorigenicand antiangiogenic agents. PPAR Res., 2008, 2008:906542.
57. Tachibana, K.; Yamasaki, D.; Ishimoto, K.; Doi, T. The role ofPPARs in cancer. PPAR Res., 2008, 2008:102737.
58. Elrod, H.A.; Sun, S.Y. PPARgamma and apoptosis in cancer.PPAR Res., 2008, 2008:704165.
59. Michalik, L.; Wahli, W. PPARs mediate lipid signaling in inflammationand cancer. PPAR Res., 2008, 2008:134059.
60. Bundscherer, A.; Reichle, A.; Hafner, C.; Meyer, S.; Vogt, T. Targetingthe tumor stroma with peroxisome proliferator activated receptor(PPAR) agonists. Anticancer Agents Med. Chem., 2009, 9,816-821.
61. Zhu, H.G.; Tayeh, I.; Israel, L.; Castagna, M. Different susceptibilityof lung cell lines to inhibitors of tumor promotion and inducersof differentiation. J. Biol. Regul. Homeost. Agents, 1991, 5, 52-58.
62. Yu, T.; Yamaguchi, H.; Noshita, T.; KIdachi, Y.; Umetsu, H.; Ryoyama, K. Selective cytotoxicity of glycyrrhetinic acid againsttumorigenic r/m HM-SFME-1 cells: potential involvement of HRasdownregulation. Toxicol. Lett., 2010, 192, 425-430.